NICE recommends Acomplia

The U.K.'s NICE issued a final appraisal determination recommending use of Acomplia rimonabant from sanofi-aventis (Euronext:SAN; SNY) on the National Health Service (NHS) to treat obese and overweight adults. In a preliminary appraisal in December, NICE recommended against use of the cannabinoid CB1 receptor antagonist and requested additional clinical data on health outcomes for patients who responded to the drug, as well as evidence of the drug's cost effectiveness (See BioCentury Extra, Thursday, Dec. 06, 2007). ...